Azienda Usl Toscana nord ovest
- Address
- Viale Vittorio Alfieri 36, 57124 Livorno, Italy
Azienda USL Toscana Nord Ovest - Oncology Research
Azienda USL Toscana Nord Ovest is a healthcare organization actively engaged in advanced oncology research, with particular emphasis on immunotherapy approaches for challenging breast cancer subtypes. The center demonstrates expertise in evaluating novel therapeutic strategies for patients with high-risk malignancies requiring intensive treatment protocols.
- Triple negative breast cancer immunotherapy trials
- Adjuvant treatment strategies with anti-PD-L1 antibodies
- Disease-free survival outcomes in high-risk breast cancer populations
The research center specializes in comprehensive clinical trials investigating Avelumab, an anti-PD-L1 antibody, for adjuvant treatment in patients with high-risk triple negative breast cancer. Their research protocols encompass diverse treatment pathways, including both neoadjuvant and adjuvant chemotherapy approaches combined with surgical interventions, reflecting a commitment to personalized cancer care and improving long-term survival outcomes for patients with aggressive breast cancer phenotypes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 9 therapeutic areas and 15 of 142 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 137 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 31 by active trials.
lock +30 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB9trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Usl Toscana nord ovest
lock Showing 1 of 82 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter Randomized Controlled Trial Comparing Short-Course Amoxicillin/Clavulanic Acid After Fever Resolution to Standard 10-Day Regimen for Febrile Urinary Tract Infections in Children | Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 142 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 22 | Unknown | 2022-04-15 | 2026-06-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.